Results from a large international phase 3 clinical trial show that the combination of immunotherapy drugs improved response rates and overall survival in previously untreated patients with intermediate- or poor-prognosis renal cell cancer. Based on the trial data, the Food and Drug Administration (FDA) approved the drug combination for these patients.
The FDA has approved tisagenlecleucel (Kymriah) for adults with certain kinds of non-Hodgkin lymphoma. Read about the clinical trial that led to the approval and what the approval means for people with lymphoma.
Results from an NCI-sponsored clinical trial may point to an important change in how some children with advanced Wilms tumor, a form of kidney cancer, are treated.
The FDA recently approved the targeted-drug combination to treat patients with advanced melanoma and a subset of patients with anaplastic thyroid cancer. Read about the trials that led to these approvals and the innovative approach to designing one of the clinical trials.
This collection of videos will help you understand the phases of a clinical trial, how your safety is protected, common issues around paying for trials, and how to find a trial for which you might be eligible.
NCI-Supported Clinical Trials that Are Recruiting Patients
This phase 2 trial is testing an experimental immunotherapy drug that targets two separate molecular functions at the same time, both stimulating the immune system and potentially preventing the cancer from blunting the immune response. Doctors want to determine the objective response rate in patients with recurrent, locally advanced, or metastatic human papillomavirus (HPV)-associated cancers not eligible for potentially curative surgery.
This phase 2 trial will help determine the best responses to nivolumab (Opdivo) immunotherapy in patients with relapsed Epstein-Barr virus (EBV)-positive non-Hodgkin lymphoma or lymphoproliferative disorders. Doctors will also monitor the toxicity of nivolumab in patients, the duration of response, and progression-free and overall survival.
Patients in this phase 1 trial will receive the immunotherapy drug pembrolizumab (Keytruda) and increasing doses of recombinant interleukin 12 (IL-12), a protein that blocks the blood supply to tumors. Doctors want to determine the safety and maximum tolerated dose of IL-12 given with pembrolizumab.
